- CROI 2013
- MICROBICIDES 2013
- IAPAC 2013
CROI 2013 – 20th Conference on Retroviruses and Opportunistic Infections
Atlanta March 3-6, 2013 - Link to conference page
The Conference on Retroviruses and Opportunistic Infections (CROI) is a scientifically focused meeting of the world’s leading researchers working to understand, prevent, and treat HIV/AIDS and its complications. The goal of CROI is to provide a forum for translating laboratory and clinical research into progress against the AIDS epidemic. Over 4,000 leading researchers and clinicians from around the world convene in a different location each year for the Conference.
• No Excess In HIV Incidence After Stopping Oral FTC/TDF Pre-Exposure Prophylaxis (PrEP) In The iPrEx Trial
Robert M. Grant (1,8), Juan Guanira (2), Susan Buchbinder (3), Carlos Mosquera (2), Valdilea Veloso (4), Esper Kallas (5), Megha Mehrotra (1), Vanessa McMahan (1), K Rivet Amico (6,7), David Glidden (8) for the iPrEx study team.
(1) Gladstone Institutes,
(2) Investigaciones Medicas en Salud,
(3) San Francisco Department of Public Health,
(4) Fundacion Oswaldo Cruz,
(5) Universidade de Sao Paulo,
(6) Center for Health Intervention and Prevention,
(7) University of Connecticut, Storrs
(8) University of California San Francisco
• Streamlining HIV testing during PrEP use: Lessons from the iPrEx trial.
Juan V Guanira (1), Teri Liegler (2), Robert Hance (3), David Glidden (2), Robert M Grant (2,3)
(1) Investigaciones Medicas en Salud,
(2) University of California, San Francisco,
(3) Gladstone Institutes
• No Evidence of Sexual Risk Compensation in the iPrEx Trial of HIV Preexposure Prophylaxis
Julia L. Marcus (1), Kenneth H. Mayer (2), Juan Vicente Guanira (3), Martin Casapia (4), Orlando Montoya-Herrera (5), Suwat Chariyalerstak (6), Linda-Gail Bekker (7), Vanessa McMahan (1), David V. Glidden (8), Robert M. Grant (1,8) for the iPrEx Study Team.
(1) Gladstone Institutes,
(2) Fenway Health,
(3) Investigaciones Medicas en Salud,
(4) Asociacion Civil Selva Amazonica,
(5) Fundacion Ecuatoriana Equidad,
(6) Research Institute for Health Sciences,
(7) Desmond Tutu HIV Foundation,
(8) University of California San Francisco
• PrEP in Young MSM: Needs and Challenges
Linda-Gail Bekker (1), Dave V Glidden (2), Sybil Hosek (3), Benjamin Brown (1), Albert Liu (4), K. Rivet Amico (5,6), Juan Guanira (7), Javier Lama (8), Vanessa McMahan (9), Robert Grant (2,9) for the iPrEx study team
(1) Desmond Tutu HIV Foundation,
(2) University of California San Francisco,
(3) Ruth M. Rothstein CORE Center Chicago,
(4) San Francisco Department of Public Health,
(5) Center for Health Intervention and Prevention,
(6) University of Connecticut, Storrs,
(7) Investigaciones Medicas en Salud,
(8) Impacta Salud y Educacion,
(9) Gladstone Institutes
• Changes in Renal Function During Use of Oral Emtricitabine/Tenofovir Disoproxil Fumarate Pre-exposure Prophylaxis in iPrEx
M 2013 - International Microbicides Conference
8th International Conference on HIV Treatment and Prevention Adherence
Miami Beach, Florida - USA, 2-4 June 2013 - Link to conference page
The goal of the 8th International Conference on HIV Treatment and Prevention Adherence is to provide an international forum for the presentation and discussion of state-of-the-science HIV treatment and biomedical prevention adherence research, as well as current behavioral and clinical perspectives in practicum. Our ultimate hope is that this dialogue translates into evidence-based implementation of approaches for real world clinical and community settings.
OBJECTIVES
After attending this conference, participants will be able to:
• Identify successes and challenges in HIV treatment adherence in various settings and populations worldwide
• Explain behavioral and clinical aspects of adherence that reflect a variety of HIV treatment team perspectives (e.g., patients, physicians, physician assistants, pharmacists, nurses, mental health professionals, adherence specialists)
• Describe current perspectives on biomedical HIV prevention interventions, including pre-exposure prophylaxis [PrEP], and antiretroviral-based microbicides
• Discuss the implications of HIV treatment and biomedical prevention adherence for individual, community, and public health
• Identify adherence assessment tools and interventions that can be integrated into patient care and/or as components of prevention interventions
• Providing drug-level feedback to US men who have sex with men (MSM) using pre-exposure prophylaxis (PrEP) in the iPrEx Open Label Extension (OLE): A qualitative evaluation of participant perspectives
Liu A, Amico KR, Koester K, McMahan V, Goicochea P, Lubensky D, Gilmore H, Chianese C, Santos K, Buchbinder S, Mayer K, Hosek S, Grant R.
• Developing and implementing a mobile health (mHealth) adherence support system for HIV-uninfected men who have sex with men (MSM) taking pre-exposure prophylaxis (PrEP): the iText Study
Liu A, Stojanovski K, Lester R, Amico KR, McMahan V, Goicochea P, Vargas L, Lubensky D, Koester K, Buchbinder S, Mayer K, Hosek S, Grant R, Fuchs, J.
- CROI 2012
- MICROBICIDES 2012
- IAPAC 2012
- AIDS 2012
- 2012 Summit
CROI 2012 - 19th Conference on Retroviruses and Opportunistics Infections
Seattle March 5 - 8, 2012 - Link to conference page
CROI is a scientifically focused meeting of the world's leading researchers working to understand, prevent, and treat HIV/AIDS and its complications.
• Intracellular Tenofovir-diphosphate (TFV-DP) Concentrations Associated with PrEP Efficacy in Men who have Sex with Men (MSM) from iPrEx
Peter L. Anderson(1), Albert Liu(2), Susan Buchbinder(2), Javier R. Lama(3), Juan Guanira(3), Vanessa McMahan(4), Lane R. Bushman(1), David Glidden(5), Robert M. Grant(4,5), and the iPrEx study team.
1 University of Colorado Denver, Aurora, CO, US~
2 San Francisco Department of Public Health, San Francisco, CA, US~
3 INMENSA, Lima, Peru~
4 Gladstone Institutes, San Francisco, CA, US
5 University of California San Francisco, San Francisco, CA, US
Download the presentation
• Effects of Tenofovir/Emtricitabine (TDF/FTC) on Body Composition in HIV-seronegative Men who have Sex with Men (MSM): Whole-body DXA Results of the iPrEx Study
Kathleen Mulligan(1), David Glidden(1), Javier Lama(2), Suwat Chariyalertsak(3), Juan Guanira-Carranza(4), Albert Liu1(5), Linda-Gail Bekker(6), Furong Wang(1), Vanessa McMahan(7), Robert Grant(1,7), and the iPrEx Study Team.
1 University of California, San Francisco, San Francisco, CA USA~
2 Investigaciones Medicas en Salud, Lima, Peru~
3 Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand~
4 Asociacion Civil Impacta Salud y Education, Lima, Peru~
5 San Francisco Department of Public Health, San Francisco, CA USA~
6 Desmond Tutu HIV Centre and Department of Medicine, University of Cape Town, Cape Town, South Africa~
7 Gladstone Institute of Virology and Immunology, San Francisco, CA USA
• Prioritizing Pre-Exposure Prophylaxis (PrEP) among Men who have Sex with Men (MSM) for Greatest Efficacy: An Analysis of the iPrEx Data.
Susan P. Buchbinder(1,2), David V.Glidden (2), J. Jeff McConnell (3), Martín Casapía(4), Orlando Montoya-Herrera(5), Valdilea G. Veloso(6), Mauro Schechter(7), Megha Mehrotra(3), Kenneth H. Mayer(6), Robert M. Grant (2,3).1 HIV Research Section, Department of Public Health, San Francisco, CA, USA;
2 University of California, San Francisco, CA, USA;
3 Gladstone Institute of Virology and Immunology, San Francisco, CA, USA;
4 Asociación Civil Selva Amazónica, Iquitos, Peru;
5 Fundación Ecuatoriana Equidad, Guayaquil, Ecuador;
6 Fundacao Oswaldo Cruz, Rio de Janeiro, Brazil,
7 Hospital Escola Sao Francisco de Assis, Rio de Janeiro, Brazil;
8 The Fenway Institute, Boston, MA, USA, for the iPrEx Study Team
M 2012 - International Microbicides Conference - From Discovery to Delivery
Sydney - Australia, 15-18 April 2012 - Link to conference page
M2012 will be a global forum for the presentation and discussion of the latest information on microbicides and oral pre-exposure prophylaxis for HIV prevention and their interface with other prevention strategies. There will be a strong emphasis on the role of community in both research and implementation of scientific findings. The conference is interdisciplinary, and will include basic science, pharmacokinetics, formulation and delivery, clinical research, public health, prevention science, and social and behavioural research.
• Next Step Counseling as a Possible Approach to Support Open Label HIV Pre-exposure Prophylaxis (PrEP) Use
Christopher Chianese (1), K Rivet Amico ( 2), Vanessa McMahan (3), Julia Marcus (3), Kenneth Mayer( 1), Robert Grant (3)
1 The Fenway Institute, Fenway Health, Boston, MA; 2 University of Connecticut, Stoors, CT; 3 The Gladstone Institute of Virology and Immunology, San Francisco, CA
• What Does It Take To Recruit High Risk Study Participants Into Biomedical HIV Prevention Studies?
Christopher Chianese, M.Ed. (1), Kenneth Mayer, MD (1), Vanessa McMahan (2), Robert Grant, MD (2) , Jake Tinsley (1)
1 The Fenway Institute, Fenway Health, Boston, MA; 2 The Gladstone Institute of Virology and Immunology, San Francisco, CA
7th International Conference on HIV Treatment and Adherence
Miami Beach, Florida - USA, 3-5 June 2012 - Link to conference page
This conference will provide a forum where the state-of-the-science for HIV treatment and biomedical prevention adherence research will be presented, discussed, and translated into evidence-based approaches. The 2.5-day program will allow healthcare and human service professionals to examine evidence-based, practical strategies to enhance and maintain adherence to HIV treatment and biomedical prevention interventions in a variety of domestic and international settings.
• Abstract No. 80467 – Integrated Next Step Counseling (iNSC)
A Discussion-Based Sexual Health Promotion Conversation to Support Men who have Sex with Men (MSM) using Pre-Exposure Prophylaxis (PrEP) in the iPrEx Open Label Extension (iPrEx OLE)
AIDS 2012- XIX International AIDS Conference
Washington DC - USA, 22-27 July 2012 - Link to conference page
The International AIDS Conference is the premier gathering for those working in the field of HIV, as well as policy makers, persons living with HIV and other individuals committed to ending the pandemic. It is a chance to assess where we are, evaluate recent scientific developments and lessons learnt, and collectively chart a course forward.
The AIDS 2012 programme will present new scientific knowledge and offer many opportunities for structured dialogue on the major issues facing the global response to HIV. A variety of session types – from abstract-driven presentations to symposia, bridging and plenary sessions – will meet the needs of various participants. Other related activities, including the Global Village, satellite meetings, exhibitions and affiliated independent events, will contribute to an exceptional opportunity for professional development and networking.
• Using Technology to Retain Young MSM in an Open Label Pre-Exposure Prophylaxis Study
M.B. Purnell (1), K. Santos(1), C. Balthazar(1), C. Orengo(1), K. Bojan(1), J. Martinez(2) & S. Hosek (2)
1 Ruth M Rothstein CORE Center, Chicago, IL.
2 Stroger Hospital of Cook County
• Correlates of Study Product Use Among U.S. Participants in the iPrEx Randomized Controlled Trial of Daily Oral Preexposure Prophylaxis
K. Rivet Amico(ab), Julia L. Marcus(c) Vanessa McMahan (c), Pedro Goicochea (cd) Lorena Vargas (d) Robert Grant (ce) Albert Liue (f).
a Applied Health Research, Brighton, MI, USA.
b Center for Health, Intervention and Prevention, University of Connecticut, CT, USA.
c Gladstone Institute of Virology and Immunology, University of California, San Francisco, CA, USA.
d Investigaciones Medicas en Salud, Lima, Peru.
e University of California, San Francisco, CA, USA.
f San Francisco Department of Public Health, San Francisco, CA, USA .
• Oral presentation at the 7th International Workshop on HIV Transmission (Friday, July 20, 9:45am): International Sexual Partnerships Shaped by Sexual Histories and Socioeconomic Status
Hong-Ha M. Truong (1,2), Megha Mehrotra (2), J. Jeff McConnell (2), Telmo Fernandez(3), Juan V. Guanira(4) and Robert M. Grant(1,2) for the iPrEx Study Team
1 University of California, San Francisco, CA, USA.
2 Gladstone Institute of Virology and Immunology, San Francisco, CA, USA.
3 Fundacion Ecuatoriana Equidad, Guayaquil, Ecuador.
4 Investigaciones Medicas en Salud, Lima, Peru.
• Poster presentation at the International AIDS Conference (Monday, July 23rd Poster Session): International Sexual Partnerships Shaped by Sexual Histories and Socioeconomic Status
Hong-Ha M. Truong (1,2), Megha Mehrotra (2), J. Jeff McConnell (2), Telmo Fernandez(3), Juan V. Guanira(4) and Robert M. Grant(1,2) for the iPrEx Study Team
1 University of California, San Francisco, CA, USA.
2 Gladstone Institute of Virology and Immunology, San Francisco, CA, USA.
3 Fundacion Ecuatoriana Equidad, Guayaquil, Ecuador.
4 Investigaciones Medicas en Salud, Lima, Peru.
2012 National Summit on HIV and Viral Hepatitis Diagnosis, Prevention and Access to Care
Washington DC November 26-28
The mission of the 2012 National Summit is to support improvement in viral hepatitis and HIV testing, prevention, and engagement in care in the United States. The nation's public health scientific and community leadership will meet to discuss state-of-the-art mechanisms to support the President's "National HIV/AIDS Strategy" (NHAS) and the HHS "Action Plan for the Prevention, Care and Treatment of Viral Hepatitis" (VHAP).
The 2012 National Summit on HIV and Viral Hepatitis Diagnosis, Prevention and Access to Care, chaired by Dr. John G. Bartlett, Dr. Kenneth H. Mayer, and Dr. Veronica Miller will be held November 26-28, 2012 at The Mayflower Renaissance Hotel Washington, DC.
ABSTRACT 2012 FOURUM FOR COLLABORATIVE HIV RESEARCH WORD COUNT
AUTHORS: K. Rivet Amico(ab) Julia L. Marcus(c) Vanessa McMahan(c) Pedro Goicochea(cd) Kimberly Koester(ce) Lorena Vargas(d) Robert Grant(cf) Ken Mayer(g) Susan Buchbinder(f) Albert Liu(cf).
(a) Applied Health Research, Brighton, MI, USA
(b) Center for Health, Intervention, and Prevention, University of Connecticut, CT, USA
(c) Gladstone Institute of Virology and Immunology, University of California, San Francisco, CA, USA
(d) Investigaciones Medicas en Salud, Lima, Peru
(e) Center for AIDS Prevention Studies, University of California, San Francisco, CA, USA
(f) University of California, San Francisco, CA, USA
(g) Fenway Institute, Brown Medical School, Boston, MA, USA
(f) San Francisco Department of Public Health, San Francisco, CA, USA
- CROI 2011
- IAPAC 2011
- IAS 2011
- AIDSImpact2011
- AIDS Vaccine 2011
- ICAAC 2011
CROI 2011 - 18th Conference on Retroviruses and Opportunistics Infections
Boston FEB 27, MAR 2 - Link to conference page
Over 4,000 leading researchers and clinicians from around the world will convene in Boston, Massachusetts from February 27 through March 2, 2011 for the 18th Conference on Retroviruses and Opportunistic Infections (CROI). CROI is a scientifically focused meeting of the world's leading researchers working to understand, prevent, and treat HIV/AIDS and its complications. The goal of CROI is to provide a forum for translating laboratory and clinical research into progress against the AIDS epidemic.
Following are the abstracts of new iPrEx study data presented at the 18th Conference on Retroviruses and Opportunistic Infections. A webcast of the study presentations will be available at the conference website (www.retroconference.org) beginning at approximately 8 p.m. EST on Tuesday, March 1, 2010.
92. Pre-exposure Chemoprophylaxis for Prevention of HIV among Trans-women and MSM: iPREx StudyRobert Grant*1, J Lama2, D Glidden3, and iPrEx Study Team
1Gladstone Inst of Virology and Immunology, San Francisco, CA, US; 2Investigaciones Medicas en Salud, Lima, Peru; and 3Univ of California, San Francisco, US
94LB. Effects of FTC/TDF on Bone Mineral Density in Seronegative Men from 4 Continents: DEXA Results of the Global iPrEx Study
Kathleen Mulligan*1, D Glidden1, PGonzales2, M-E Ramirez-Cardich3, A Liu1,4, S Namwongprom5, PChodacki6, L Mendonc¸a7,VMcMahan8, R Grant1,8, and iPrEx Study Team
1Univ of California, San Francisco, US; 2Investigaciones Medicas en Salud, Lima, Peru; 3Assn Civil Impacta Salud y Ed, Lima, Peru; 4San Francisco Dept of Publ Hlth, CA, US; 5Chiang Mai Univ, Thailand; 6Desmond Tutu HIV Fndn, Cape Town, South Africa; 7Federal Univ of Rio de Janeiro, Brazil; and 8Gladstone Inst of Virology and Immunology, San Francisco, CA, US
95LB. Adherence Indicators and PrEP Drug Levels in the iPrEx Study
Rivet Amico*1, A Liu2, VMcMahan3, PAnderson4, J Lama5, J Guanira5, J-H Zheng4, D Glidden6, and R Grant3
1Univ of Connecticut, Storrs, US; 2San Francisco Dept of Publ Hlth, CA, US; 3Gladstone Inst of Virology and Immunology, San Francisco, CA, US; 4Univ of Colorado Denver, Aurora, US; 5Investigaciones Medicas en Salud, Lima, Peru; and 6Univ of California, San Francisco, US
96LB. Interpreting Detection Rates of Intracellular FTC-TP and TFV-DP: The iPrEx Trial
Peter Anderson*1, J Lama2, S Buchbinder3, J Guanira4, O Montoya5, M Casapia6, L Bragg7, L Bushman1, D Glidden8, R Grant7,8, and iPrEx Study Team
1Univ of Colorado Denver, Aurora, US; 2Investigaciones Medicas en Salud, Lima, Peru; 3San Francisco Dept of Publ Hlth, CA, US; 4Assn Civil Impacta Salud y Ed, Lima, Peru; 5Fndn Ecuatoriana Equidad, Guayaquil-Guayas, Ecuador; 6Assn Civil Selva Amazonica, Iquitos, Maynas, Peru; 7Gladstone Inst of Virology and Immunology, San Francisco, CA, US; and 8Univ of California, San Francisco, US
97LB. Drug Resistance and Minor Drug Resistant Variants in iPrEx
Teri Liegler*1, M Abdel-Mohsen1, R Atchison2, M Mehotra2, T Schmidt1, C Eden2, D Glidden1, S Buchbinder1,3, J Lama4, R Grant1,2, and iPrEx Study Team
1Univ of California, San Francisco, US; 2Gladstone Inst of Virology and Immunology, San Francisco, CA, US; 3San Francisco Dept of Publ Hlth, CA, US; and 4Investigaciones Medicas en Salud, Lima, Peru
1002. Oral TDF and Its Impact in HSV-2 Acquisition and Clinical Expression
Javier Lama*1, K Mayer2, M Schechter3, E Kallas4, L-G Bekker5, S Chariyalertsak6, S Shiboski7, R Grant7,8, and iPrEx Study Team
1Investigaciones Medicas en Salud and Assn Civil Impacta Salud y Ed, Lima, Peru; 2Fenway Hlth, Boston, MA, US; 3Federal Univ of Rio de Janeiro, Brazil; 4Univ of Sao Paulo Sch of Med, Brazil; 5Desmond Tutu HIV Ctr, Univ of Cape Town, South Africa; 6Res Inst for Hlth Sci, Chiang Mai Univ, Thailand; 7Univ of California, San Francisco, US; and 8Gladstone Inst of Virology and Immunology, San Francisco, CA, US
6th International Conference on HIV Treatment and Adherence
Miami, FL.; May 22-24, 2011
The goal of the 6th International Conference on HIV Treatment and Prevention Adherence is to provide an international forum for the presentation and discussion of state-of-the-science HIV treatment and biomedical prevention adherence research, as well as current behavioral and clinical perspectives in practicum.
www.confmanager.com/main.cfm?cid=2289
Following is the abstract on iPrEx study data on adherence presented at the 6th International Conference on HIV Treatment and Prevention Adherence 2011, IAPAC. (http://www.iapac.org)
Defining and Predicting Detection Rates of Intracellular Emtricitabine-Triphosphate (FTC-TP) and Tenofovir-Diphosphate (TFV-DP) in the iPrEx HIV Pre-Exposure Prophylaxis (PrEP) Trial
6th IAS Conference on HIV Pathogenesis, Treatment and Prevention
The world's largest open scientific conference on HIV/AIDS – the 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011) will be held in Rome Italy in July 2011. The event will be organized by the IAS, in partnership with Istituto Superiore di Sanità (Italian National Institute of Health), which is the leading technical and scientific body of the Italian National Health Service.
Held every two years, the conference attracts about 5,000 delegates from all over the world. It is a unique opportunity for the world's leading scientists, clinicians, public health experts and community leaders to examine the latest developments in HIV-related research, and to explore how scientific advances can – in very practical ways – inform the global response to HIV/AIDS.
To access the conference web site click the following link: www.ias2011.org/
WELBC04, Oral: "Completed observation of the randomized placebo-controlled phase of iPrEx: daily oral FTC/TDF pre-exposure HIV prophylaxis among men and trans women who have sex with men"
R.M. Grant; Wednesday, July 20, 16:30-17:30; Session room 2
MOLBPE035, Poster: "Acute pre-seroconversion HIV infection at baseline prior to starting oral or topical pre-exposure prophylaxis: iPrEx and CAPRISA 004"
R.M. Grant; Poster session time: Sunday, 17 July, 12:30– 14:30
MOLBPE043, Poster: "Local risk Indicators key for targeting PrEP"
M. Merhotra; Poster session time: Sunday, 17 July, 12:30– 14:30
MOLBPE034, Poster: "Expanded case-control analysis of drug detection in the global iPrEx trial"
P. Anderson; Poster session time: Monday, 18 July, 12:30– 14:30
MOLBPE037, Poster: "Hair as a biological marker of daily oral pre-exposure prophylaxis (PrEP) adherence and tenofovir/emtricitabine (TFV/FTC) exposure in the Global iPrEx Study"
A. Liu; Poster session time: Monday, 18 July 12:30 – 14:30
MOLBPE039, Poster: "Social adverse events experienced by trans women and other men who have sex with men (MSM) participating in a HIV pre-exposure prophylaxis (PrEP) trial"
P. Goicochea; Poster session time: Monday, 18 July 12:30 – 14:30
MOPE393, Poster: "Strategizing communications for successful dissemination of study results in HIV prevention trials: the case of the iPrEx study"
P. Goicochea; Poster session time: Monday, 18 July 12:30 – 14:30
TUPE363, Poster: "Adherence/drug detection rates and study participant experiences of counseling support among MSM in the iPrEx pre-exposure prophylaxis (PrEP) trial in San Francisco, United States"
H. Gilmore; Poster session time: Tuesday, 19 July 12:30 – 14:30
TULBPE024, Poster: "Depression among men who have sex with men (MSM) at risk for HIV infection in the Global iPrEx Study"
A. Liu; Poster session time: Tuesday, 19 July 12:30 – 14:30
CDB467, E-Poster: "Low bone mineral density in Peruvian young men at high risk for HIV infection: Risk Factors"
P. Gonzales
CDC214, E-Poster: "Forgotten risk, remembered sex: standard HIV risk questions underestimate sex in networks"
J. McConnell
10th International Conference on Biospsychosocial Aspects of HIV Infection
Santa Fe, New Mexico, September 12th - 15th, 2011
The Focus of AIDS IMPACT is to create a network between biological, psychological and social aspects of HIV.
The Conference will connect researchers, practitioners and users to share knowledge, resources, innovations and new ideas.
AIDS IMPACT provides a multi-disciplinary and cross-cultural forum to allow research to inform practice and deliver expertise to where it is needed most, as strategies and methods of treatment, intervention, prevention and care.
The Conference is an excellent opportunity for people working and living with HIV disease, throughout the world to engage in dialogue and debate.
http://www.aidsimpact.com/2011/
Session 20.1, Pedro Goicochea: The iPrEx Trial: A Case Study
The field of pre-exposure prophylaxis (PrEP) trials has always been controversial. Now, after three trials showing efficacy in different populations, the controversy continues to exist. This session will present a brief history of the conduct of the iPrEx trial, the first PrEP trial to show the efficacy of PrEP for HIV prevention as a case study.
The iPrEx study or PrEP Initiative stands for Chemoprophylaxis for HIV Prevention in Men, a trial that showed, in November 2010, that PrEP with FTC/TDF provides 44% additional protection from HIV infection; and is the first and only clinical study in gay men, transgender women and other men who have sex with men at high risk of acquiring HIV.
The iPrEx trial was conducted at 11 sites in six countries on four continents after three years of preparation and broad consultation with the community, national authorities and other stakeholders following good participatory practices (GPP) and ethical principles in biomedical research as recommended by UNAIDS/WHO.
The iPrEx trial is rolling over participants on an open label extension observational study where participants will receive active FTC/TDF for 72 weeks and this will be an opportunity to assess if adherence and drug exposure increase when participants know about safety and efficacy of the PrEP; and if sexual behavior changes.
AIDS Vaccine 2011
Bangkok, Thailand, 12th-15th September 2011
The Faculty of Tropical Medicine, Mahidol University and the Department of Disease Control, Ministry of Public Health, Thailand, will serve as Local Hosts for AIDS Vaccine 2011, the largest and most important global scientific conference focused on AIDS vaccine research. AIDS Vaccine 2011 will be held 12-15 September 2011 in Bangkok, Thailand. This annual international conference brings together scientists, community advocates, funders, and policy makers from around the world to hear cutting-edge scientific results, exchange new ideas, educate future leaders, and engage a diverse community of scientists in the quest for an HIV vaccine.
www.vaccineenterprise.com/conference/2011/
Immunological protection from HIV infection in the iPrEx trial
Peter J Kuebler (*1), Sara J Holditch(1⌃), Leandro F Tarrosso(2⌃), Jeff J McConnell(3⌃),Megha Mehrotra(3), Brian I Shaw(1), R. Andre Raposo(1), Rex G Cheng(1), Emily M Eriksson(1), Vanessa McMahan(3), Robert J Hance(3), Patricia Defechereux(3), Jeanny Lee(3), Teri Liegler(1), Stephen Shiboski(1), Susan Buchbinder(4), David V Glidden(1), Robert M Grant(3§), Douglas F. Nixon(1§) and Esper G. Kallas(2§).
1University of California, San Francisco, USA 2University of São Paulo, Brazil, 3Gladstone Institute for Virology and Immunology, San Francisco, USA 4San Francisco Department of Public Health * Presenting Author, ⌃Equal Contributor, §Co-Senior Authors
Men who have sex with men at risk for HIV infection were enrolled in the iPrEx trial of pre-exposure prophylaxis. 2499 HIV-seronegative men or transgender women who have sex with men received a combination of two oral antiretroviral drugs, emtricitabine and tenofovir disoproxil fumarate (FTC–TDF), or placebo. 100 study participants became infected during the follow-up period (36 in the FTC–TDF group and 64 in the placebo group), indicating a 44% reduction in the incidence of HIV. Oral FTC–TDF provided protection against the acquisition of HIV infection among these subjects (Grant et al, NEJM 2010). This population provided a unique opportunity to explore potential immunological correlates that may contribute to protection against acquisition of HIV. Previous case studies have reported on types of immunity which may be associated with such protection in exposed but uninfected individuals. We performed an analysis of HIV-specific cell mediated immunity in participants enrolled in the iPrEx trial using a standard IFN-γ ELISPOT assay. We hypothesized that exposure to HIV before enrollment and during the study period could have stimulated immune responses which protected against HIV acquisition. Individuals who remained seronegative in the iPrEx trial had stronger anti-HIV T cell responses than the responses in the pre-infection period of those who eventually seroconverted, mean of 296 vs 48 SFU/106 PBMC respectively, p<0.00001, and a greater breadth of responses. Strong and broad HIV-specific immune responses are a correlate of protection from acquisition of HIV in the iPrEx trial.
51th ICAAC: Interscience Conference on Antimicrobial Agents and Chemotherapy Meeting
Chicago, IL, September 16th -20th, 2011
Join 10,000 of your colleagues from around the world at the world's premier meeting on infectious diseases and antimicrobial agents. This fall, world renowned scientists will converge in Chicago to exchange information and foster global solutions to scientific challenges such as HIV/AIDS, anthrax, smallpox, SARS, bioterrorism preparedness, recognition, detections, and medical treatments. Through abstracts, symposia, and other educational opportunities ICAAC will provide timely information that will improve healthcare and the management of infectious diseases.
Antiretroviral for PrEP: Next Steps Following iPrEx Results, Robert Grant, MD, MPH